This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinicaltrials involving cannabis. To date, the US National Institute on Drug Abuse designates the University of Mississippi to be the sole provider of marijuana for FDA-approved research.
The American Psychological Association (APA) is urging US Attorney General William Barr to review more than two-dozen pending applications for federal marijuana grow licenses. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue. Also on Wednesday, Rep.
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinicaltrials’. BRC) told The Cannigma this week.
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle.
The Denver cannabis company MedPharm can now ramp up its research into the effects marijuana has on Alzheimer’s disease. The new DEA research license will now change that. It’s possible because of a new Schedule I Researcher License granted by the Drug Enforcement Administration. credit: CBS).
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
Marijuana Moment report. The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2
The post House Passes Bipartisan Bill Facilitating Clinical Cannabis Research, Allowing Scientists to Access State-Approved Marijuana Products appeared first on NORML.
The action represents one of the very few occasions that members of the Senate have ever advanced a marijuana-related reform bill. Under this proposal, the AG is also provided with the ability to authorize increases in the total number of federally approved marijuana cultivators. BILLS-117s253es. The full text of S.
It seems like every day I read a new story about legislators, high-ranking federal officials, and frustrated advocates of marijuana research complaining that researchers still can’t study the actual marijuana that people are using in the state-legal markets. Use the plants for their own studies and/or FDA clinicaltrials.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.
The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA View original article.
Funding of Marijuana Research. research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. In Canada, recreational marijuana use was legalized in October 2018. stance on marijuana.
In clinicaltrials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinicaltrials underway in the U.S. We know such categorization is baseless and false.
THC is responsible for marijuana’s psychoactive effects. CBD’s also known for its calming, pain-relieving effects – although, it’s important to point out that THC-rich products are more often recommended for severe pain (to learn more, see: Marijuana & Cancer Pain ). Hemp VS. Marijuana. One more difference?
Canada legalized recreational marijuana for the entire country. took significant steps to decriminalize or legalize medical or recreational marijuana. In December, Israel became the fifth country to pass legislation legalizing the export of medical marijuana (after the Netherlands, Canada, Uruguay, and Australia).
Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. Drug Enforcement Agency (DEA). The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market.
Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. The quality of this cannabis had been criticised by a number of researchers, including Dr. Sisley.
The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree.
This year, we are completing the second Phase 3 clinicaltrial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Members of Congress voiced support for marijuana/AIDS research.
When you’re talking about wanting to do an actual clinicaltrial, you need a diversity of people that participate and one state just does not have the diversity of people that are required,” Towle said. Denver Company Moves Forward with Research License . Denver’s MedPharm Drives Research Further.
This compound is produced in very small amounts in marijuana and hemp, but most of what is on the market today is converted synthetically in a lab and sold in amounts largely unseen in nature. . The only clinicaltrial on delta-8-THC involving humans was done on children in Israel in 1995. Delta-8-THC research.
The sale will greatly reduce the current and future burn rate of the company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the U.S. location.
The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. With a goal of determining the “the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”. MAPS Makes History.
The only psychedelic drug that is approved (outside of clinicaltrials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. Schedule I.
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinicaltrials. Differing brands of marijuana could interact with the already current use of general anesthesia,” Vaibhav theorizes. .
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinicaltrials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.
Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Back in 2018, the DEA rescheduled GW Pharmaceuticals ‘ (NASDAQ: GWPH) cannabis-based epilepsy medicine, Epidiolex, following its regulatory approval by the FDA. Fortunately, this issue shouldn’t be a show-stopper.
A long-awaited clinicaltrial on using cannabis as a treatment for veterans with PTSD has finally been published in the PLOS One journal , but the results are far less promising than researchers and veterans had hoped. million grant from the Multidisciplinary Association of Psychedelic Studies (MAPS).
Mounting evidence shows cannabinoids in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find.
health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .
For years, many military veterans have used medical marijuana to manage the symptoms of PTSD. For Veterans With PTSD, Medical Marijuana Can Mean a Good Night’s Sleep. for the production of cannabis used in federally-regulated clinicaltrials. Wasn’t the DEA going to let others grow research-grade cannabis?
Dr Stuart Titus the CEO at Medical Marijuana Inc. is an industry innovator who has been involved in the growth of many companies in the cannabis industry, and started his relationship with Medical Marijuana Inc. His first-hand experience with therapeutic hemp oil products as nutritional supplements led him to Medical Marijuana Inc.
It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinicaltrials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.
One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.
It is now deemed an agricultural commodity, no longer able to be classified as a controlled substance, like marijuana. Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%.
One of the main reasons why “marijuana” remains a federally illegal, Schedule I controlled substance is that, according to the Feds, it has no currently accepted medical use. Ole Miss got the cannabis study and research cultivation gig from the DEA (via a contract with the National Institute on Drug Abuse (NIDA)) in 1968.
DMT, like its sister psychedelics (LSD, MDMA, psilocybin … and even marijuana), is a Schedule I controlled substance. So according to the DEA, its abuse potential is high and it has no medical use. In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinicaltrial this past summer.
President Joe Biden has officially signed a marijuana research bill into law. 8454, the “Medical Marijuana and Cannabidiol Research Expansion Act,” has been passed. attorney general 60 days to either approve a given application or request supplemental information from the marijuana research applicant. The law gives the U.S.
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. ClinicalTrials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.
I will not cover the legal status of marijuana or any other substance. Unlike marijuana which contains large quantities of the cannabinoid THC that is responsible for making you feel high, CBD will not make you high. Most states have different laws and regulations individually pertaining to CBD and marijuana. What is CBD?
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Sisley just entered the national spotlight, known as the research doctor who’d been unfairly fired from the University of Arizona for simply trying to study medical marijuana.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content